Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Nigeria Pharmaceuticals & Healthcare Report Q1 2014 - New Study Released


Print article Print article
2013-12-04 10:06:26 - New Healthcare market report from Business Monitor International: "Nigeria Pharmaceuticals & Healthcare Report Q1 2014"

Medicines demand in Nigeria will be driven by urbanisation, rising per capita incomes, a growing burden on non-communicable diseases and the government's plans to increase widespread healthcare access to all citizens. However, we note that government spending is significantly dependent on oil and gas revenues and, as such, any fall in prices of these commodities is likely to cause a decline in government investment in healthcare. Key downside risks to foreign multinational investment include low pharmaceutical per capita spending, weak patent respect and poor business transparency. Headline Expenditure Projections

* Pharmaceuticals: NGN174.5bn (US$1.10bn) in 2012 to NGN203.8bn (US$1.28bn) in 2013; +16.8% in local currency terms and +16.5% in US dollar terms. Forecasts revised slightly downwards due to modifications to historical

figures.
* Healthcare: NGN2,356.4bn (US$14.8bn) in 2012 to NGN2,720.9bn (US$17.1bn) in 2013; +15.5% in local currency terms and +15.2% in US dollar terms. Forecasts broadly in line with Q413.

Full Report Details at
- www.fastmr.com/prod/723484_nigeria_pharmaceuticals_healthcare_re ..

Risk/Reward Rating:

In Q114, Nigeria maintained its Q413 Pharmaceutical Risk/Reward Rating (RRR) score of 38 out of 100, although it jumped three places from 21st position to 18th position in the Middle East and Africa matrix. Nigeria is regarded as a low-reward, high-risk proposition for multinationals due to drug counterfeiting, corruption and poor pharmaceutical regulations governing the market.

Key Trends And Developments

August 2013

The Nigerian Federal Government announced that as of June 30 2014, the sale of pharmaceutical drugs outside regulated sales channels will be banned. Manufacturers and importers will be required to channel their medicines to State and Mega Drug Distribution Centres (SMDDCs) - introduced by the National Agency For Food, Drug Administration and Control (NAFDAC) - as a provision of the new National Drug Distribution Guidelines. The current uncoordinated drug distribution system is largely responsible for the circulation of counterfeit medicines in the pharmaceutical sector.

GlaxoSmithKline Nigeria registered an 8.3% year-on-year increase in pre-tax profit to NGN2.09bn (US $13mn) in H113, ended June 30 2013, in comparison with NGN1.93bn (US$12.03mn) in H112. The company's turnover rose to NGN13.99bn (US$87.1mn) in the reported period, compared with NGN12.84bn (US$79.9mn) in H112. In addition, GSK also withdrew its plan to increase its share in the Nigerian unit to 75% after opposition from minority stakeholders.

July 2013

Director of NAFDAC, Paul Orhii, reported that Nigeria produces less than 30% of essential medicines consumed in the country due to local pharmaceutical companies' poor production capacities. Orhii cited the country's low drug manufacturing potential as one of the reasons for the increasing threat of fake and substandard drugs in the country.

BMI Economic View: The Nigerian economy still faces major headwinds in the crucial oil and gas sector, but other sectors, notably agriculture, have started to pick back up. We are forecasting real GDP growth of 6.7% in 2013, a rate below Nigeria's substantial potential but a slight improvement on the previous year.

BMI Political View: President Goodluck Jonathan's decision to dismiss nine cabinet ministers linked to a breakaway faction of the ruling party suggests that the embattled leader has no intention of negotiating with the rebels. We expect political tensions to increase, and believe that the split could pose a risk to Jonathan's re-election in 2015

Partial Table of Contents:

BMI Industry View
SWOT
- Political
- Economic
- Business Environment
Industry Forecast
- Pharmaceutical Market Forecast
- Table: Nigeria Pharmaceutical Sales, Historical Data And Forecasts
- Healthcare Market Forecast
- Table: Nigeria Healthcare Expenditure Trends, Historical Data And Forecasts
- Table: Nigeria Government Healthcare Expenditure Trends, Historical Data And Forecasts
- Table: Table: Nigeria Private Healthcare Expenditure Trends, Historical Data And Forecasts
- Prescription Drug Market Forecast
- Table: Nigeria Prescription Drug Market Indicators, Historical Data And Forecasts
- Patented Drug Market Forecast
- Table: Nigeria Patented Drug Market Indicators, Historical Data And Forecasts
- Generic Drug Market Forecast
- Table: Nigeria Generics Drug Market Indicators, Historical Data And Forecasts
- OTC Medicine Market Forecast
- Table: Nigeria Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts
- Pharmaceutical Trade Forecast
- Table: Nigeria Pharmaceutical Trade Data And Forecasts (NGNmn)
- Other Healthcare Data
- Key Risks To BMI's Forecast Scenario
Macroeconomic Forecasts
- Economic Analysis
- Table: Nigeria - Economic Activity
Industry Risk Reward Ratings
- Nigeria Risk/Reward Ratings
- Rewards
- Risks
- Middle East And Africa Risk/Reward Ratings
Market Overview
Industry Trends And Developments
- Epidemiology
- Maternal And Child Health
- Non-Communicable Diseases
- Communicable Disease
- Healthcare Sector
- Healthcare Sector Developments
- Healthcare Financing
- Healthcare Provision
- Health Insurance
- Traditional Medicine
- Telemedicine
- Research & Development
- Clinical Trials
Regulatory Development
- Regulatory Regime
- Domestic Drugmakers
- Intellectual Property Regime
- Pricing And Reimbursement Regime
- National Drug Policy
- Medical Tourism
Competitive Landscape
- Domestic Industry
- Foreign Industry
- Pharmaceutical Distribution
Company Profile
- Nigerian-German Chemicals (NGC)
- Emzor Pharmaceutical Industries
- Fidson Healthcare
- May & Baker
- Neros Pharmaceuticals

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=723484&dt=t

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser